AGEN logo

Agenus Inc.

AGEN
Healthcare|Biotechnology|US
$7.15
+0.71 (+11.02%)
Graham Number
$1.18
Cash / Share
$1.39
Next Earnings Report
Mar 15, 2027
EPS est. -$0.30 · Revenue est. $28.0M
Financing Filings (last 12 months)
5
Shelf registrations / offering prospectuses — latest Sep 11, 2026 (S-3). Possible dilution.

Upcoming Data Readouts (18)

Dec 2026
Est. completion
P2Colorectal Cancer Metastatic
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
NCT06300463n=24
Dec 2026
Est. completion
P1P2Refractory Metastatic Colorectal Cancer
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers
NCT05205330n=107
Jan 2027
Est. completion
Early P1Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis
Botensilimab, Balstilimab, and SBRT in Colorectal Cancer
NCT07128355n=15
Apr 2027
Est. completion
P2Metastatic Soft Tissue Sarcoma
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
NCT04028063n=65
Jun 2027
Est. completion
P2Early Rectal Cancer
RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer
NCT07735624n=16
Sep 2027
Est. completion
P2Metastatic Colorectal Cancer
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
NCT05608044n=234
Oct 2027
Est. completion
P1P2Metastatic Prostate Cancer
A Study of Evofosfamide in Combination With Zalifrelimab and Balstilimab
NCT06782555n=71
Feb 2028
Est. completion
P2Microsatellite Stable Rectal Carcinoma
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
NCT06843434n=40
May 2028
Est. completion
P3Gastric Cancer
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
NCT06346197n=132
Jul 2028
Est. completion
P2Colorectal Cancer
Botensilimab and Balstilimab Optimization in Colorectal Cancer
NCT06268015n=16
Dec 2028
Est. completion
P1P2Pancreatic Cancer
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
NCT06782932n=38
Jan 2029
Est. completion
P2P3Resectable MMR-deficient Solid Tumors
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations
NCT06279130n=133
Sep 2029
Est. completion
P2Lymphoma
Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
NCT05891821n=20
Nov 2029
Est. completion
P1Colorectal Cancer
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
NCT06411691n=54
Apr 2030
Est. completion
P2Non-small Cell Lung Cancer
Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)
NCT06322108n=45
Aug 2030
Est. completion
P2Metastatic Pancreatic Ductal Adenocarcinoma
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
NCT06843551n=20
Nov 2030
Est. completion
P2Colorectal Cancer
A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy
NCT07227636n=284
Jul 2031
Est. completion
P2Newly Diagnosed Glioblastoma
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
NCT05864534n=25

Awaiting Results (3)

Trials past primary completion date but still active — data readout may be imminent.

Aug 2026
P2
AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC
NCT05632328
Apr 2025
P1P2
Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer
NCT04827953
Jan 2025
P1
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
NCT03860272

Recent Press Releases

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
Nov 6, 2026 · Business Wire
Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study
Nov 5, 2026 · Business Wire
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
Nov 2, 2026 · Business Wire
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Nov 2, 2026 · Business Wire
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
Oct 25, 2026 · Business Wire
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
Oct 22, 2026 · Business Wire
Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference
Oct 9, 2026 · Business Wire
Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
Oct 8, 2026 · Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Oct 3, 2026 · Business Wire
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Oct 2, 2026 · Business Wire

SEC Filings (68)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 202610-QQuarterly reportDocumentIndex
Nov 5, 20268-KMaterial eventDocumentIndex
Sep 11, 2026S-3Shelf registrationDocumentIndex
Sep 2, 2026S-8Employee stock planDocumentIndex
Aug 18, 20268-KMaterial eventDocumentIndex
Aug 17, 2026424B3Offering prospectusDocumentIndex
Aug 14, 2026EFFECTDocumentIndex
Aug 13, 20268-KMaterial eventDocumentIndex
Aug 11, 20268-KMaterial eventDocumentIndex
Aug 7, 202610-QQuarterly reportDocumentIndex
Aug 7, 2026S-8Employee stock planDocumentIndex
Aug 7, 2026S-3Shelf registrationDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Jul 27, 2026EFFECTDocumentIndex
Jul 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 20, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 20, 2026S-3Shelf registrationDocumentIndex
Jul 17, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 13, 20268-KMaterial eventDocumentIndex
Jul 6, 20268-KMaterial eventDocumentIndex
Jun 23, 20268-KMaterial eventDocumentIndex
May 15, 20268-KMaterial eventDocumentIndex
May 13, 2026DEFA14AProxy / shareholder voteDocumentIndex
May 11, 202610-QQuarterly reportDocumentIndex
May 11, 20268-KMaterial eventDocumentIndex
Apr 30, 2026ARSAnnual report to holdersDocumentIndex
Apr 30, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 20, 2026PRE 14AProxy / shareholder voteDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 26, 20268-KMaterial eventDocumentIndex
Mar 16, 202610-KAnnual reportDocumentIndex
Mar 16, 20268-KMaterial eventDocumentIndex
Jan 23, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Jan 16, 20268-KMaterial eventDocumentIndex
Jan 14, 20268-KMaterial eventDocumentIndex
Jan 8, 20268-KMaterial eventDocumentIndex
Dec 29, 2025S-3ASRShelf registrationDocumentIndex
Nov 10, 202510-QQuarterly reportDocumentIndex
Nov 10, 20258-KMaterial eventDocumentIndex
Oct 30, 2025SC 13G/APassive 5%+ stakeDocumentIndex